Skip to main navigation
Skip to search
Skip to main content
The Ohio State University Home
Search content at The Ohio State University
Home
Profiles
Research units
Research output
Projects
The Potential Role of B cell-targeted therapies in multiple sclerosis
Aaron Boster
, Daniel P. Ankeny
, Michael K. Racke
Center for Clinical and Translational Science
Neurology
Research output
:
Contribution to journal
›
Article
›
peer-review
22
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The Potential Role of B cell-targeted therapies in multiple sclerosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Multiple Sclerosis
100%
B Cell-targeted Therapy
100%
B Cells
83%
Multiple Sclerosis Treatment
33%
Demyelination
33%
Clinical Trials
16%
Pathophysiology
16%
T Cells
16%
Therapeutic Intervention
16%
Therapeutic Target
16%
T Cell Activation
16%
Cerebrospinal Fluid
16%
Cytokine Production
16%
Immunoglobulin
16%
Rituximab
16%
Demyelinating Diseases
16%
Plasma Cells
16%
Antibody Secretion
16%
Antigen Presentation Cell
16%
Medicine and Dentistry
Targeted Therapy
100%
Multiple Sclerosis
100%
B Cell
100%
Clinical Trial
14%
T Cell
14%
Pathophysiology
14%
Secretion (Process)
14%
Cerebrospinal Fluid
14%
T Cell Activation
14%
Remyelination
14%
Demyelination
14%
Cytokine Production
14%
Rituximab
14%
Antigen Presentation
14%
Clinically Isolated Syndrome
14%
Treatment of Multiple Sclerosis
14%
Immunoglobulin Producing Cell
14%
Antibody Generation
14%
Immunology and Microbiology
B Cell
100%
Multiple Sclerosis
100%
T Cell
14%
Clinically Isolated Syndrome
14%
Secretion (Process)
14%
Cerebrospinal Fluid
14%
T Cell Activation
14%
Cytokine Production
14%
Treatment of Multiple Sclerosis
14%
Remyelinization
14%
Rituximab
14%
Antigen Presentation
14%
Immunoglobulin Blood Level
14%
Immunoglobulin Producing Cell
14%
Antibody Generation
14%
Neuroscience
Multiple Sclerosis
100%
B Cell
100%
T Cell
28%
Demyelinating Disease
14%
Remyelinization
14%
Treatment of Multiple Sclerosis
14%
Cytokine Production
14%
Rituximab
14%
Cell Activation
14%
Immunoglobulin Producing Cell
14%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Cytokine
12%
Clinical Trial
12%
Pathophysiology
12%
Demyelinating Disease
12%
Rituximab
12%
Demyelination
12%